Results 121 to 130 of about 3,046 (215)

Model‐Informed Recommendation of Mavacamten Posology for Chinese Adults With Obstructive Hypertrophic Cardiomyopathy

CPT: Pharmacometrics & Systems Pharmacology
Mavacamten is a cardiac myosin inhibitor for adults with obstructive hypertrophic cardiomyopathy (HCM). Dose optimization is performed 4 weeks after starting mavacamten, guided by periodic echo measurements of Valsalva left ventricular outflow tract ...
Xiaojie Wu, Shilpa Puli, Nanye Chen, Zhuang Tian, Peiwen Hsu, Jing Sun, Cheng Lyu, Samira Merali, Jing Zhang   +8 more
doaj   +1 more source

Hypertrophic Cardiomyopathy with Special Focus on Mavacamten and Its Future in Cardiology

Biomedicines
Hypertrophic cardiomyopathy (HCM) is a heterogeneous group of heart muscle disorders that affects millions, with an incidence from 1 in 500 to 1 in 200. Factors such as genetics, age, gender, comorbidities, and environmental factors may contribute to the
Ewelina Młynarska, Ewa Radzioch, Bartłomiej Dąbek, Klaudia Leszto, Alicja Witkowska, Witold Czarnik, Weronika Jędraszak, Jacek Rysz, Beata Franczyk   +8 more
doaj   +1 more source

Mavacamten Cardiac Myosin Inhibitor: Clinical Applications and Future Perspectives

Cureus
Mavacamten is a first-in-class, selective allosteric inhibitor of cardiac myosin adenosine triphosphatase (ATPase) that has emerged as a novel therapeutic option for patients with symptomatic hypertrophic obstructive cardiomyopathy (HOCM) who remain ...
Mahmoud M. Ramadan, Raghad A Al-Najjar, Rokia S Abady, Hala A Obaid, Yasmeen A Mostafa, Mohammad T Al-Obeid, Mohammed Elmahal   +6 more
semanticscholar   +1 more source

Forest plot showing KCCQ-CSS score of the Mavacamten group compared to placebo at random effect.

Forest plot showing KCCQ-CSS score of the Mavacamten group compared to placebo at random effect.
Kalgi Modi (7699319), Mansunderbir Singh (18405132), Anuj Thakre (18405138), Sahith Reddy Thotamgari (15947040), Rahul Vyas (18405123), Shubhika Jain (17719146), Viraj Panchal (18405126), Keerthish Jaisingh (18405135), Manush Sondhi (18405129)   +8 more
core   +1 more source

Pharmacogenetic testing to broaden patient eligibility for mavacamten

European Heart Journal - Cardiovascular Pharmacotherapy
The European Medicines Agency (EMA) approved mavacamten in June 2023 for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM).1,2 Clinical trials have demonstrated its efficacy in improving exercise capacity, reducing the left ventricular outflow tract (LVOT) gradient, and alleviating symptoms, and decreases the need for invasive
Lorenz Van der Linden, Lucas Van Aelst, Iacopo Olivotto   +2 more
openaire   +3 more sources

Anterior mitral valve leaflet length and response to mavacamten in obstructive hypertrophic cardiomyopathy

European heart journal. Imaging methods and practice
Objectives This study examines whether anterior mitral valve leaflet (AMVL) length is associated with response to mavacamten in patients with obstructive hypertrophic cardiomyopathy (HCM).
D. Saleh, Ellis Y. Kim, Kifah Hussain, V. Appadurai, Kayla Mueller, Abigail Garza, Baljash Cheema, Dominic E. Fullenkamp, Vera H. Rigolin, A. Narang, Paul C. Cremer, L. Choudhury   +11 more
semanticscholar   +1 more source

The effect of mavacamten on echocardiographic parameters, cardiac function and biomarkers in hypertrophic cardiomyopathy patients, a systematic review and meta-analysis

Indian Heart Journal
Background: Evaluate the effect of mavacamten on echocardiographic parameters and cardiac biomarkers in patients with hypertrophic cardiomyopathy (HCM).
Zina Otmani, Noura Abdrabou, Hazem Ayman Elsayed, Mazen Negmeldin Aly Yassin, Mohamed Abouzid, Mahmoud Diaa Hindawi, Ayman K. Awad   +6 more
doaj   +1 more source

Myosin Modulator Aficamten Inhibits Force by Altering Myosin’s Biochemical Activity Without Changing Thick Filament Structure

JACC: Basic to Translational Science
Summary: We investigated the effects of aficamten on cardiac muscle structure, biochemical activity, and contractile function. Aficamten does not structurally sequester myosin heads along the thick filament.
Saffie Mohran, PhD, Kristina B. Kooiker, PhD, Ateeqa Naim, BS, Matvey Pilagov, BS, Anthony Asencio, BS, Kyrah L. Turner, BS, Weikang Ma, PhD, Galina Flint, MD., Siyao Jiang, BS, Jing Zhao, BS, Timothy S. McMillen, PhD, Christian Mandrycky, PhD, Max Mahoney-Schaefer, BS, Thomas C. Irving, PhD, Bertrand C.W. Tanner, PhD, Neil M. Kad, PhD, Michael Regnier, PhD, Farid Moussavi-Harami, MD   +17 more
doaj   +1 more source

Evaluating the efficacy and safety of mavacamten in hypertrophic cardiomyopathy: A systematic review and meta-analysis focusing on qualitative assessment, biomarkers, and cardiac imaging.

PLoS ONE
BackgroundHypertrophic Cardiomyopathy (HCM) is a complex cardiac condition characterized by hypercontractility of cardiac muscle leading to a dynamic obstruction of left ventricular outlet tract (LVOT).
Rahul Vyas, Viraj Panchal, Shubhika Jain, Manush Sondhi, Mansunderbir Singh, Keerthish Jaisingh, Sahith Reddy Thotamgari, Anuj Thakre, Kalgi Modi   +8 more
doaj   +1 more source

Efficacy and safety of Mavacamten for symptomatic Hypertrophic cardiomyopathy – an updated Meta-Analysis of randomized controlled trials

International Journal of Cardiology: Heart & Vasculature
Hypertrophic cardiomyopathy (HCM) is an autosomal dominant disorder with risk of sudden cardiac death (SCD) in children and adolescents. Mavacamten, also referred to as MYK-461, a myosin inhibitor of cardiac myocytes is studied in symptomatic HCM.
Irfan Ullah, Syeda Tayyaba Rehan, Zayeema Khan, Syed Hasan Shuja, Muhammad Hamza Shuja, Muhammad Irfan, Karthik Gonuguntla, M Chadi Alraies, Pratik Aggarwal, Sameer Raina, Yasar Sattar, Muhammad Sohaib Asghar   +11 more
doaj   +1 more source